Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Inhibition of experimental asthma by indoleamine 2,3-dioxygenase
Tomoko Hayashi, … , Dennis A. Carson, Eyal Raz
Tomoko Hayashi, … , Dennis A. Carson, Eyal Raz
Published July 15, 2004
Citation Information: J Clin Invest. 2004;114(2):270-279. https://doi.org/10.1172/JCI21275.
View: Text | PDF
Article Immunology

Inhibition of experimental asthma by indoleamine 2,3-dioxygenase

  • Text
  • PDF
Abstract

Epidemiological evidence points to the inverse relationship between microbial exposure and the prevalence of allergic asthma and autoimmune diseases in Westernized countries. The molecular basis for this observation has not yet been completely delineated. Here we report that the administration of certain toll-like receptor (TLR) ligands, via the activation of innate immunity, induces high levels of indoleamine 2,3-dioxygenase (IDO), the rate-limiting enzyme of tryptophan catabolism in various organs. TLR9 ligand–induced pulmonary IDO activity inhibits Th2-driven experimental asthma. IDO activity expressed by resident lung cells rather than by pulmonary DCs suppressed lung inflammation and airway hyperreactivity. Our results provide a mechanistic insight into the various formulations of the hygiene hypothesis and underscore the notion that activation of innate immunity can inhibit adaptive Th cell responses.

Authors

Tomoko Hayashi, Lucinda Beck, Cyprian Rossetto, Xing Gong, Osamu Takikawa, Kenji Takabayashi, David H. Broide, Dennis A. Carson, Eyal Raz

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
The impact of ISS-ODN–induced cytokines on IDO expression levels. (A) We...
The impact of ISS-ODN–induced cytokines on IDO expression levels. (A) Western blot of lung homogenates (40 μg protein) from TNF-α, IL-12p40, and IFN-γ KO mice and WT mice that were injected i.v. with ISS-ODN (20 μg). (B–D) Lung CD11c+ cells were isolated from WT or IFN-γ KO (γ-KO) mice (five mice per group) that were injected i.v. with ISS-ODN (ISS) (20 μg/mouse). IDO expression was assessed by RT-PCR (B), Western blot (C), and measurements of enzymatic activity (KYN assay) (D). *P < 0.05, ISS-ODN–treated vs. PBS-treated group.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts